Neuphoria Therapeutics (NEUP)
NASDAQ:NEUP
Top Page
Neuphoria Therapeutics
(NASDAQ:NEUP)
Select Model
Select Model
Rating:62Neutral
Price Target:
$4.00
▼(-13.79% Downside)
Action:ReiteratedDate:03/24/26
The score is primarily supported by the 2025 financial step-change (revenue emergence, near-breakeven losses, very low leverage, and strong positive cash flow). Offsetting this, technicals are only mildly positive with a weak longer-term trend versus the 200-day average, and the very low P/E is tempered by uncertainty around the sustainability of 2025 results and the lack of a dividend.
Positive Factors
Strong cash generation (2025)
In 2025 Neuphoria converted to strong positive operating and free cash flow (~+$77.2M) after years of burn. Durable cash generation materially improves optionality for funding R&D, supporting operations, or executing strategic transactions without immediate equity dilution.
Negative Factors
Volatile cash flow and revenue sustainability risk
The 2025 cash inflow is large but follows multiple years of cash burn, suggesting timing-driven or non-recurring items. Reliance on a single-year cash swing undermines predictability of funding and could force recapitalization or curtailed investment if cash proves non-repeatable.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong cash generation (2025)
In 2025 Neuphoria converted to strong positive operating and free cash flow (~+$77.2M) after years of burn. Durable cash generation materially improves optionality for funding R&D, supporting operations, or executing strategic transactions without immediate equity dilution.
Read all positive factors
Neuphoria Therapeutics (NEUP) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$23.29M
Dividend YieldN/A
Average Volume (3M)89.21K
Price to Earnings (P/E)2.4
Beta (1Y)1.69
Revenue GrowthN/A
EPS GrowthN/A
CountryUS
Employees8
SectorHealthcare
Sector Strength45
IndustryMedical - Pharmaceuticals
Share Statistics
EPS (TTM)N/A
Shares Outstanding5,390,895
10 Day Avg. Volume91,705
30 Day Avg. Volume89,214
Financial Highlights & Ratios
PEG Ratio-0.16
Price to Book (P/B)0.40
Price to Sales (P/S)0.48
P/FCF Ratio0.15
Enterprise Value/Market Cap-0.60
Enterprise Value/Revenue-1.70
Enterprise Value/Gross Profit-1.78
Enterprise Value/Ebitda0.02
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Neuphoria Therapeutics Business Overview & Revenue Model
Company Description
Neuphoria Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. The company was founded on December 23, 2024 and is head...
Neuphoria Therapeutics Financial Statement Overview
Summary
Income Statement
44
Neutral
Balance Sheet
78
Positive
Cash Flow
70
Positive
| Breakdown | TTM | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 8.21M | 23.95M | 0.00 | 0.00 | ― | 0.00 |
| Gross Profit | 7.86M | 22.94M | -992.56K | -671.42K | 0.00 | -1.69M |
| EBITDA | -846.20M | -268.02K | -22.33M | -21.54M | -28.03M | -6.63M |
| Net Income | -373.34M | -565.77K | -23.19M | -21.65M | -22.94M | -8.65M |
Balance Sheet | ||||||
| Total Assets | 36.60M | 43.44M | 27.65M | 19.39M | 44.93M | 40.77M |
| Cash, Cash Equivalents and Short-Term Investments | 22.17M | 21.59M | 12.61M | 8.06M | 23.09M | 21.41M |
| Total Debt | 50.13K | 226.49K | 272.74K | 257.55K | 477.15K | 652.04K |
| Total Liabilities | 6.90M | 14.57M | 10.16M | 4.74M | 5.78M | 5.01M |
| Stockholders Equity | 29.70M | 28.87M | 17.49M | 14.65M | 39.15M | 35.76M |
Cash Flow | ||||||
| Free Cash Flow | 74.79M | 77.23M | -14.68M | -9.85M | -14.97M | -5.67M |
| Operating Cash Flow | 74.79M | 77.23M | -14.68M | -9.85M | -14.97M | -5.66M |
| Investing Cash Flow | 0.00 | 0.00 | 0.00 | 0.00 | 427.68K | -60.26K |
| Financing Cash Flow | 1.55B | 1.53B | 15.11M | 2.60M | 18.57M | 23.71M |
Neuphoria Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
62 Neutral | $23.29M | 2.36 | -1538.29% | ― | ― | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $38.97M | -0.59 | -281.00% | ― | ― | 15.35% | |
46 Neutral | $25.46M | -33.14 | 0.27% | ― | 75.19% | ― | |
42 Neutral | $10.43M | -0.63 | -204.04% | ― | -60.89% | 94.49% | |
| ― | $11.09M | -0.38 | -94.79% | ― | ― | 84.44% |
* Healthcare Sector Average
NEUP
Neuphoria Therapeutics
4.32
-0.32
-6.90%
TXMD
TherapeuticsMD
2.20
1.30
144.44%
SINT
Sintx Technologies
2.53
0.43
20.48%
RNTX
Rein Therapeutics
1.39
-0.25
-15.24%
BIVI
BioVie
1.47
-6.53
-81.63%
BFRG
BullFrog AI Holdings, Inc.
1.07
-0.45
-29.61%
Neuphoria Therapeutics Corporate Events
Business Operations and StrategyExecutive/Board Changes
Neuphoria Therapeutics Announces CEO Transition and Consulting Role
Neutral
Jan 8, 2026
Neuphoria Therapeutics Inc. announced that Spyridon “Spyros” Papapetropoulos, M.D., who was appointed president and CEO under an employment agreement effective January 5, 2023, will step down as full-time president and CEO effective De...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.